Nippon Chemiphar Struggles Despite New Launches

Japanese Company Bogged Down By COVID-19 And NHI Price Revisions

Nippon Chemiphar saw its overall sales drop by 7.9%, dragged down by a fall in generics sales of 9.7%, in its financial first half ended 30 September 2020. The Japanese company’s plan to ride on the success of new launches faltered as it was unable to compensate for the impact of NHI drug price revisions implemented in October 2019 and again in April 2020. 

arrow_downwards
Nippon Chemiphar has revised its guidance to account for the impact of the pandemic • Source: Shutterstock

Nippon Chemiphar saw its generics sales slide down by 9.7% year-on-year to ¥12.28bn ($118m) in its financial first half ended 30 September 2020, compared to ¥13.61bn reported in the prior-year period, mainly due to National Health Insurance drug price revisions made in October 2019 and again in April 2020, as well as the impact of the coronavirus pandemic. In its non-pharmaceutical “other” segment too, Nippon Chemiphar saw its sales drop by 25.3% YoY as “the COVID-19 pandemic caused delays related to contracted testing.”

In March 2020, Nippon Chemiphar had reported that its operating profit more than halved since it was “unable to compensate...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business